HTG Appoints William Radany CEO.
"Bill Radany is a proven industry leader who brings more than 20 years of experience in the pharmaceutical and drug discovery technologies industries to HTG," said Bruce Seligmann, chairman, HTG. "His strong leadership and management skills will be instrumental in guiding the company's pursuit of both short and long-term growth objectives."
"I am excited to work closely with the Board of Directors and the management team at HTG to continue to bring the Company's gene expression profiling technology to the forefront of drug discovery research. HTG's technology platform brings tremendous value to lab researchers," said Dr. Radany. "With my experience at life sciences and biotech companies alike, I'm looking forward to applying my experience and insight at HTG to take the business to the next level and expand the Company's customer base which currently includes leading pharmaceutical companies such as Merck & Co., Sanofi Aventis, Bristol Meyers Squibb, Celgene and Takeda, Inc."
Prior to Chemicon International, Dr. Radany was chief business officer at Xencor where he headed up corporate strategy for partnering of Xencor proteomics technologies. He has also served as vice president of drug discovery programs at both Caliper Technologies Corp. and Strategene respectively. Prior to Strategene, Dr. Radany was president of Biacore, a proteomics technology company and previously founded the in vitro diagnostic cell culture company NeoGenex and subsequently sold the Company to Diagnostic Hybrids, Inc.
Dr. Radany earned a B.S. in cell biology from Colorado State University and a doctorate in biochemistry/physiology from the University of Wyoming.
HTG's ArrayPlate qNPA(TM) technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG's ArrayPlate lysis-only quantitative Nuclease Protection Assay (qNPA(TM)) platform allows scientists to test any sample while avoiding the need for extraction or target amplification. The platform provides robust, high-quality quantitative test results, including QSAR-quality dose response data and EC50's, enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.
HTG provides ArrayPlate qNPA technology and services for the life sciences industry, addressing current unmet needs and enabling a new era of drug discovery and diagnostics. The company's ArrayPlate technology platform enables the accurate, sensitive, reproducible and repeatable measurement of molecular signatures through the multiplexed measurement of RNA expression levels, DNA and protein levels and function. ArrayPlate qNPA data measure how drugs act and diseases are mediated at the level of whole cells, tissues, or organisms. This enables researchers to focus their resources by rapidly obtaining higher quality results than possible with other methods, in days rather than months, saving time and cost while addressing critical unmet needs. Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, and Village Ventures. Additional information is available at www.htgenomics.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 18, 2006|
|Previous Article:||Del Monte Promotes Healthy Living with New Products and Partners at American Dietetic Association's 2006 Conference.|
|Next Article:||Ramtron to Supply FRAM Memory to Ampy Automation for Arizona Salt River Project Utility Meters.|